Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(1.25)
# 3,372
Out of 4,786 analysts
27
Total ratings
39.13%
Success rate
-10.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNMD Mind Medicine (MindMed) | Initiates: Outperform | $23 | $5.85 | +293.16% | 1 | Jan 28, 2025 | |
| CABA Cabaletta Bio | Downgrades: In-Line | $15 → $6 | $1.39 | +333.21% | 2 | Dec 20, 2024 | |
| ARGX argenx SE | Maintains: Outperform | $675 → $706 | $591.87 | +19.28% | 4 | Nov 21, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $179 → $170 | $63.82 | +166.37% | 9 | Nov 7, 2024 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $65 | $4.30 | +1,411.63% | 2 | Aug 26, 2024 | |
| FHTX Foghorn Therapeutics | Initiates: Outperform | $20 | $3.65 | +447.95% | 1 | Aug 19, 2024 | |
| KRYS Krystal Biotech | Maintains: Outperform | $201 → $206 | $180.30 | +14.25% | 1 | Aug 12, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $62 → $66 | $45.05 | +46.50% | 2 | Aug 8, 2024 | |
| ACRS Aclaris Therapeutics | Initiates: Outperform | $22 | $1.53 | +1,337.91% | 1 | Oct 3, 2023 | |
| CCCC C4 Therapeutics | Maintains: Outperform | $20 → $10 | $1.60 | +525.00% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $159 → $165 | $209.52 | -21.25% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $13.99 | +328.88% | 1 | Oct 5, 2022 |
Mind Medicine (MindMed)
Jan 28, 2025
Initiates: Outperform
Price Target: $23
Current: $5.85
Upside: +293.16%
Cabaletta Bio
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $1.39
Upside: +333.21%
argenx SE
Nov 21, 2024
Maintains: Outperform
Price Target: $675 → $706
Current: $591.87
Upside: +19.28%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $63.82
Upside: +166.37%
Jasper Therapeutics
Aug 26, 2024
Maintains: Outperform
Price Target: $65
Current: $4.30
Upside: +1,411.63%
Foghorn Therapeutics
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $3.65
Upside: +447.95%
Krystal Biotech
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $180.30
Upside: +14.25%
Mirum Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $62 → $66
Current: $45.05
Upside: +46.50%
Aclaris Therapeutics
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $1.53
Upside: +1,337.91%
C4 Therapeutics
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $1.60
Upside: +525.00%
Feb 9, 2023
Maintains: Outperform
Price Target: $159 → $165
Current: $209.52
Upside: -21.25%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $13.99
Upside: +328.88%